A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

Tantai, Narisa; Chaikledkaew, Usa; Tanwandee, Tawesak; Werayingyong, Pitsaphun; Teerawattananon, Yot

doi:10.1186/1472-6963-14-170

BMC Health Services Research

Table 1 Input parameters used in economic model

From: A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

Parameter	Distribution	Mean	SE	Reference
Yearly discount rate (%)
Costs and outcomes (range)		3 (0-6)		[51]
Transitional probability baseline parameters
Probability of stable to CHB state	Beta	0.143	0.0650	[31]
Probability of CHB to stable state	Beta	0.056	0.0180	[32]
Probability of CHB to compensated in 1^st-10^th year	Beta	0.054	0.0543	[33]
Probability of CHB to compensated in 11^th-20^th year	Beta	0.134	0.1338	[33]
Probability of CHB to compensated in >20^th year	Beta	0.329	0.3292	[33]
Probability of CHB to HCC in 1^st-5^th year	Beta	0.000	0.0000	[34]
Probability of CHB to HCC in 6t^h-10^th year	Beta	0.006	0.0061	[34]
Probability of CHB to HCC in >10^th year	Beta	0.008	0.0081	[34]
Probability of CHB to death in 1^st-5^th year	Beta	0.010	0.0102	[34]
Probability of CHB to death in 6^th-10^th year	Beta	0.014	0.0144	[34]
Probability of CHB to death in >10^th year	Beta	0.025	0.0252	[34]
Probability of compensated to decompensated in 1^st-3^rd year	Normal	0.042	0.0003	[35]
Probability of compensated to decompensated in 4^th-5^th year	Normal	0.094	0.0005	[35]
Probability of compensated to decompensated in >5^th year	Normal	0.066	0.0003	[35]
Probability of compensated to HCC in 1^st-3^rd year	Normal	0.014	0.0002	[35]
Probability of compensated to in HCC 4^th-5^th year	Normal	0.036	0.0003	[35]
Probability of compensated to HCC in >5^th year	Normal	0.030	0.0002	[35]
Probability of compensated to death in 1^st-3^rd year	Beta	0.014	0.0135	[35]
Probability of compensated to death in >3^rd year	Beta	0.046	0.0461	[35]
Probability of decompensated to HCC	Beta	0.035	0.0354	[36]
Probability of decompensated to death in 1^st year	Normal	0.260	0.0004	[37]
Probability of decompensated to death in 2^nd year	Normal	0.390	0.0005	[37]
Probability of decompensated to death in >2^nd year	Normal	0.240	0.0003	[37]
Probability of HCC to death in 1^st year	Beta	0.848	0.0011	[37]
Probability of HCC to death in >1^st year	Beta	0.920	0.0009	[37]
Transitional probability of treatment parameters
Probability of CHB to compensated	Beta	0.006	0.0023	[38]
Probability of CHB to HCC	Beta	0.009	0.0045	[39]
Probability of CHB to death	Beta	0.002	0.0023	[39]
Probability of compensated to HCC	Beta	0.015	0.0034	[40]
Probability of compensated to death	Beta	0.007	0.0070	[39]
Probability of decompensated to HCC	Beta	0.035	0.0127	[41]
Probability of decompensated to death	Beta	0.126	0.0291	[42]
Probability of compensated to CHB	Beta	0.478	0.0665	[43]
Probability of HCC to death	Beta	0.034	0.0227	[44]
Relative risk of seroconversion of lamivudine	Normal	3.519	1.3707	[30]
Relative risk of seroconversion of adefovir	Normal	3.028	1.3833	[30]
Relative risk of seroconversion of telbivudine	Normal	4.286	1.4054	[30]
Relative risk of seroconversion of entecavir	Normal	3.846	1.3833	[30]
Relative risk of seroconversion of pegylated interferon	Normal	5.356	1.4987	[30]
Relative risk of seroconversion of tenofovir	Normal	4.167	1.6403	[30]
Probability of delay seroconversion of pegylated interferon	Normal	0.410	0.0489	[27]
Probability of lamivudine resistance	Beta	0.214	0.0214	[28]
Probability of adefovir resistance	Beta	0.066	0.0066	[28]
Probability of telbivudine resistance	Beta	0.089	0.0089	[28]
Probability of entecavir resistance	Beta	0.002	0.0002	[28]
Probability of tenofovir resistance	Beta	0.000	0.0000	[28]
Annual direct medical cost
Cost of generic lamivudine	Gamma	1,797	180	[46]
Cost of original lamivudine	Gamma	34,871	3,487	[46]
Cost of adefovir	Gamma	70,298	7,030	[46]
Cost of telbivudine	Gamma	51,504	5,150	[46]
Cost of entecavir	Gamma	85,745	8,575	[46]
Cost of tenofovir	Gamma	15,559	1,556	[46]
Cost of pegylated interferon	Gamma	527,379	52,738	[46]
Cost of treatment of compensated cirrhosis	Gamma	81,264	81,264	[48]
Cost of treatment of decompensated cirrhosis	Gamma	125,127	125,127	[48]
Cost of treatment of HCC	Gamma	153,021	153,021	[48]
Cost of laboratory for screening (i.e., HBeAg, HBeAb)	Gamma	650	650	[47]
Cost of laboratory for pre-treatment	Gamma	3,350	3,350	[47]
Cost of laboratory for monitoring	Gamma	4,200	4,200	[47]
Cost of laboratory monitoring for pegylated interferon	Gamma	10,620	10,620	[47]
Cost of laboratory monitor for adefovir	Gamma	4,560	4,560	[47]
Cost of laboratory for post-treatment	Gamma	4,900	4,900	[47]
Annual direct non-medical cost
Cost of transportation	Gamma	571	571	[54]
Cost of food	Gamma	210	210	[54]
Annual indirect cost
Cost of time loss due to receiving treatment	Gamma	824	824	[49]
Cost of productivity loss of compensated cirrhosis	Gamma	48	48	[48, 49]
Cost of productivity loss of decompensated cirrhosis	Gamma	627	627	[48, 49]
Cost of productivity loss of HCC	Gamma	1,701	1,701	[48, 49]
Utility
Utility weight for CHB	Normal	0.68	0.00005	[53]
Utility weight for compensated cirrhosis	Normal	0.69	0.00016	[53]
Utility weight for decompensated cirrhosis	Normal	0.35	0.00031	[53]
Utility weight for HCC	Normal	0.38	0.00026	[53]

Back to article page

ISSN: 1472-6963

Contact us

General enquiries: journalsubmissions@springernature.com